What's Going On With Iovance Biotherapeutics Today?
Portfolio Pulse from Dylan Berman
Iovance Biotherapeutics (NASDAQ: IOVA) shares are trading higher following the announcement of promising clinical data for lifileucel in combination with pembrolizumab for treating frontline advanced melanoma. The data, to be presented at the 2024 ASCO Annual Meeting, showed a 65.2% overall response rate in patients. HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating with a $32 price target.
May 24, 2024 | 3:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iovance Biotherapeutics shares are trading higher after revealing promising clinical data for lifileucel in combination with pembrolizumab for treating frontline advanced melanoma. The data showed a 65.2% overall response rate, supporting the TILVANCE-301 trial. HC Wainwright reiterated a Buy rating with a $32 price target.
The positive clinical data and the reiteration of a Buy rating with a high price target are likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100